Fig. 5

Hypo-MSC enhances lipogenesis via AKT/mTOR/SREBP1 pathway. a Protein levels of AKT, mTOR and SREBP1 in indicated cells. b Immunofluorescence of SREBP1 in 7402 and Hep3b. c-d Protein levels of AKT, mTOR and SREBP1 in YAP KD or YAP OE cells. e Protein levels of AKT, mTOR and SREBP1 in YAP knockdown (siYAP) cells under indicated conditions. f Protein levels of AKT, mTOR and SREBP1 in YAP OE cells treated with AKT inhibitor LY294002. g Cellular content of TG were detected in YAP OE cells treated with AKT inhibitor LY294002 (n = 3). h The content of neutral lipids was detected by BODIPY 493/503 dye staining in YAP OE cells treated with AKT inhibitor LY294002. (*p < 0.05, **p < 0.01)